BC Week In Review | Feb 9, 2015
Financial News

Summit proposes follow-on

Summit Corp. plc (LSE:SUMM), Abingdon, U.K.   Business: Musculoskeletal, Endocrine/Metabolic, Infectious   Date announced: 2015-01-30   Type: Follow-on   To be raised: Up to $40 million   Shares: TBD   Price prior: 127.5p   Underwriters:...
BC Innovations | Oct 2, 2014
Tools & Techniques

A CRISPR possibility for DMD

CRISPR-based genome editing has filled the headlines since its discovery about two years ago for its ability to modify specific sequences in the genome with high accuracy, but its impact to date has been mainly...
BC Week In Review | Jul 21, 2014
Clinical News

SMT19969 regulatory update

Summit said FDA granted Qualified Infectious Disease Product (QIDP) designation to SMT19969 to treat Clostridium difficile infection (CDI). The oral, small molecule, heterocyclic antibiotic is in Phase II testing to treat C. difficile-associated diarrhea (CDAD)....
BC Week In Review | Jul 14, 2014
Clinical News

SMT19969: Phase II started

Summit began the double-blind, North American Phase II CoDIFy trial to compare 200 mg oral SMT19969 twice daily for 10 days vs. 125 mg oral vancomycin given 4 times a day for 10 days in...
BC Week In Review | Jun 30, 2014
Company News

Summit management update

Summit Corp. plc (LSE:SUMM), Abingdon, U.K.   Business: Musculoskeletal, Endocrine/Metabolic, Infectious   Hired: Erik Ostrowski as CFO  ...
BC Week In Review | Mar 24, 2014
Clinical News

SMT19969: Phase II start

This half, Summit will begin the double-blind, North American Phase II CoDIFy trial to compare 200 mg oral SMT19969 twice daily vs. 125 mg oral vancomycin given 4 times a day for 10 days in...
BC Week In Review | Mar 10, 2014
Financial News

Summit completes placing

Summit Corp. plc (LSE:SUMM), Abingdon, U.K.   Business: Musculoskeletal, Endocrine/Metabolic, Infectious   Date completed: 3/4/14   Type: Placing   Raised: £22 million ($36.8 million)   Shares: 338.5 million   Price: 6.5p   Shares after offering:...
BC Innovations | Dec 19, 2013
Translation in Brief

Translational tidbits

Consorting with academia GlaxoSmithKline plc has set up an immuno-oncology consortium that invites academics from six cancer centers to view its nonpublic early pipeline programs and share ideas for new therapeutic candidates. The Oncology Clinical...
BC Week In Review | Dec 16, 2013
Clinical News

SMT C1100: Phase Ib started

Summit began an open-label, dose-escalation, U.K. Phase Ib trial to evaluate 3 doses of oral SMT C1100 daily for 10 days in 12 DMD patients ages 5-11 years. The trial will use a nanoparticle aqueous...
BC Week In Review | Dec 9, 2013
Company News

Summit, University of Oxford deal

Summit and the university partnered to develop treatments for Duchenne muscular dystrophy (DMD). Under the deal, Summit will acquire MuOx Ltd., an Oxford spinout that houses exclusive rights to utrophin modulators and core screening technology,...
Items per page:
1 - 10 of 109
BC Week In Review | Feb 9, 2015
Financial News

Summit proposes follow-on

Summit Corp. plc (LSE:SUMM), Abingdon, U.K.   Business: Musculoskeletal, Endocrine/Metabolic, Infectious   Date announced: 2015-01-30   Type: Follow-on   To be raised: Up to $40 million   Shares: TBD   Price prior: 127.5p   Underwriters:...
BC Innovations | Oct 2, 2014
Tools & Techniques

A CRISPR possibility for DMD

CRISPR-based genome editing has filled the headlines since its discovery about two years ago for its ability to modify specific sequences in the genome with high accuracy, but its impact to date has been mainly...
BC Week In Review | Jul 21, 2014
Clinical News

SMT19969 regulatory update

Summit said FDA granted Qualified Infectious Disease Product (QIDP) designation to SMT19969 to treat Clostridium difficile infection (CDI). The oral, small molecule, heterocyclic antibiotic is in Phase II testing to treat C. difficile-associated diarrhea (CDAD)....
BC Week In Review | Jul 14, 2014
Clinical News

SMT19969: Phase II started

Summit began the double-blind, North American Phase II CoDIFy trial to compare 200 mg oral SMT19969 twice daily for 10 days vs. 125 mg oral vancomycin given 4 times a day for 10 days in...
BC Week In Review | Jun 30, 2014
Company News

Summit management update

Summit Corp. plc (LSE:SUMM), Abingdon, U.K.   Business: Musculoskeletal, Endocrine/Metabolic, Infectious   Hired: Erik Ostrowski as CFO  ...
BC Week In Review | Mar 24, 2014
Clinical News

SMT19969: Phase II start

This half, Summit will begin the double-blind, North American Phase II CoDIFy trial to compare 200 mg oral SMT19969 twice daily vs. 125 mg oral vancomycin given 4 times a day for 10 days in...
BC Week In Review | Mar 10, 2014
Financial News

Summit completes placing

Summit Corp. plc (LSE:SUMM), Abingdon, U.K.   Business: Musculoskeletal, Endocrine/Metabolic, Infectious   Date completed: 3/4/14   Type: Placing   Raised: £22 million ($36.8 million)   Shares: 338.5 million   Price: 6.5p   Shares after offering:...
BC Innovations | Dec 19, 2013
Translation in Brief

Translational tidbits

Consorting with academia GlaxoSmithKline plc has set up an immuno-oncology consortium that invites academics from six cancer centers to view its nonpublic early pipeline programs and share ideas for new therapeutic candidates. The Oncology Clinical...
BC Week In Review | Dec 16, 2013
Clinical News

SMT C1100: Phase Ib started

Summit began an open-label, dose-escalation, U.K. Phase Ib trial to evaluate 3 doses of oral SMT C1100 daily for 10 days in 12 DMD patients ages 5-11 years. The trial will use a nanoparticle aqueous...
BC Week In Review | Dec 9, 2013
Company News

Summit, University of Oxford deal

Summit and the university partnered to develop treatments for Duchenne muscular dystrophy (DMD). Under the deal, Summit will acquire MuOx Ltd., an Oxford spinout that houses exclusive rights to utrophin modulators and core screening technology,...
Items per page:
1 - 10 of 109